Susan Elizabeth Sharp MD, Abstract Co-Author: Nothing to Disclose

Andrew Timothy Trout MD, Presenter: Nothing to Disclose

Michael J. Gelfand MD, Abstract Co-Author: Nothing to Disclose

This exhibit will review key information related to the imaging of pediatric neuroblastoma with I-123 MIBG and the treatment of stage IV neuroblastoma with I-131 MIBG. Key teaching points will include: Proper scan preparation and technique are critical for obtaining high quality MIBG images Knowledge of the normal biodistribution of MIBG is essential for accurate scan interpretation SPECT/CT imaging helps identify disease sites and aids in differentiating sites of physiologic uptake Curie scoring can be used to quantitate disease extent and response I-131 MIBG therapy requires meticulous technique and specific imaging/follow-up protocols

1. Scan preparation     a. Thyroid blockade     b. Medication cessation 2. Normal scan     a. MIBG uptake mechanism     b. Biodistribution (including SPECT) 3. Imaging technique     a. Timing     b. Collimator choice     c. Planar whole body images     d. Spot lateral skull images     e. SPECT and SPECT/CT 4. Curie scoring 5. I-131 MIBG therapy     a. Patient preparation     b. Caregiver preparation     c. Dosing     d. Technologist/staff safety     e. Post-therapy imaging Interpretation Biodistribution Collimator choice    f. Discharge requirements     g. Follow-up

http://abstract.rsna.org/uploads/2014/14003933/14003933_ogc8.pdf

Sharp, S, Trout, A, Gelfand, M, MIBG and Neuroblastoma: Everything You Need to Know.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14003933.html